contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Initiator Pharma is a biotechnology company. Today, the main focus is to develop drug candidates to be used in treatment of erectile dysfunction in men. The company currently has pharmaceuticals in clinical stage testing for patients that do not respond on PDE5i pharmaceuticals. Initiator Pharma was created as a spin-off from Saniona and is today based in Åbyhøj.

Initiator Pharma

Business highlights in Q2 2024In April the company announced the publication of pudafensine preclinical pharmacology results in the British Journal of PharmacologyBusiness highlights after this...

<div class="mfn-preamble"><p><strong>Business highlights in Q2 2024</strong></p></div><div class="mfn-body"><ul><li>In April the company announced the publication of pudafensine preclinical pharmacology results in the British Journal of Pharmacology</li></ul><p><strong>Business highlights after this reporting period</strong></p><ul><li>In July the company announced the publication of the international patent application regarding pudafensine’s dosage regime for the treatment of erectile dysfunction</li></ul><p><strong>Financial Highlights</strong></p><table><tbody><tr><td rowspan="1" colspan="1"><strong>Second Quarter (2024-04-01 – 2024-06-30)</strong></td></tr><tr><td rowspan="1" colspan="1">Net revenue were TDKK 0 (0)</td></tr><tr><td rowspan="1" colspan="1">Operating loss, EBIT was TDKK -4,991 (-8,882)</td></tr><tr><td rowspan="1" colspan="1">Earnings per share before and after dilution was DKK –0.09 (-0.20)</td></tr><tr><td rowspan="1" colspan="1">Cash: TDKK 14,487 (25,935)</td></tr><tr><td rowspan="1" colspan="1">Solidity: 94% (45%)</td></tr></tbody></table><table><tbody><tr><td rowspan="1" colspan="1"><strong>First Six Months (2024-01-01 – 2024-06-30)</strong></td></tr><tr><td rowspan="1" colspan="1">Net revenues were TDKK 0 (0)</td></tr><tr><td rowspan="1" colspan="1">Operating loss, EBIT was TDKK -8,568 (-17,559)</td></tr><tr><td rowspan="1" colspan="1">Earnings per share before and after dilution was DKK –0.16 (-0.38)</td></tr></tbody></table><p><em>Solidity: equity divided by assets.</em></p><p>The Board of Directors have decided that interim reports will be published in English only.</p><p><strong>Link to the full report</strong><br><a rel="noopener" href="https://www.initiatorpharma.com/en/investors/reports-and-presentations/">https://www.initiatorpharma.com/en/investors/reports-and-presentations/</a></p></div><div class="mfn-footer mfn-contacts mfn-8e6161468890"><p><strong class="mfn-heading-1">For additional information about Initiator Pharma, please contact:</strong></p><hr><p>Claus Elsborg Olesen, CEO<br>Telephone: +45 6126 0035<br>E-mail:&nbsp;<a rel="noopener" href="mailto:ceo@initiatorpharma.com">ceo@initiatorpharma.com</a></p></div><div class="mfn-footer mfn-about mfn-cdb0015b163c"><p><strong class="mfn-heading-1">About Initiator Pharma</strong></p><hr><p>Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine (IP2015) and IP2018 – and two preclinical assets. The company is currently conducting a Phase IIb trial with pudafensine (IP2015) in erectile dysfunction of organic origin, and successfully completed a Phase I proof of principle trial in neuropathic pain in 2022. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.<br>&nbsp;<br>Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit <a rel="noopener" href="http://www.initiatorpharma.com.">www.initiatorpharma.com.</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/ae5cabbe-6f0b-434f-9b27-e0a008e58856/q2-2024-initiator-final.pdf" class="mfn-primary">Q2 2024 Initiator Final</a></p></div>

Stay up to date with our newsletter